Table 2.

Preclinical Studies on Complement Inhibition

Authors	Models	Animals	Interventions	Effects
Silasi-Mansat54	Infusion with 1×109 live E coli (LD50 dose)	Baboons	C3 convertase inhibitor: Compstatin was administered as a 10-mg/kg intravenous bolus followed by 60 μg/kg/min continuous infusion	Reduction in inflammatory and hemostatic processes, Improvement in systemic blood pressure and organ function
Silasi-Mansat55	Infusion with 1×109 live E coli (LD50 dose)	Baboons	C3 convertase inhibitor: Compstatin was administered as a 10-mg/kg intravenous bolus followed by 60 μg/kg/min continuous infusion	Reduction in early profibrogenic responses in the lung, including fibroblast differentiation, cell migration and proliferation, and the enhanced production of collagens and other matrix proteins.
Czermak56	Cecal ligation and puncture	Rats	IgG antibody against C5a	Improvement in survival rates Reduction in levels of bacteremia
Laudes57	Cecal ligation and puncture	Rats	Rabbit Anti-Rat C5a	Improvement in survival rates Improvement in platelet counts, fibrinogen, FVII:C, AT, plasminogen, t-PA, and PAI as well as TAT complexes and D-dimer
Barratt-Due58	Live E. coli sepsis	Pigs	C5 and leukotriene B4 inhibitor Ornithodoros moubata complement inhibitor (OmCI; coversin) alone and combined with anti-CD14	Reduction in proinflammatory mediators and in thrombogenicity, Increase in IL-10, Delayed hemodynamic changes
Skjeflo59	Live E. coli sepsis	Pigs	C5 and leukotriene B4 inhibitor Ornithodoros moubata complement inhibitor (OmCI; coversin) alone and combined with anti-CD14	Improvement in survival Improvement in pulmonary and systemic hemodynamic Reduction in proinflammatory mediators
Sun60	Intratracheal inoculation with 10650% tissue culture infective dose (TCID50) of A/Anhui/1/2013 (H7N9) virus	Green monkeys	Neutralizing specific antihuman C5a antibody (IFX-1)	Reduction in the ALI and systemic inflammation Reduction in lung viral replication